Abstract:The conversion of proteins from their native state into well-organized fibrillar aggregates, whether inside cells or in the extracellular space of connective tissue, leads to the pathogenesis of several human diseases that include neurodegenerative diseases as well as non-neuropathic conditions, such as systemic amyloidosis. Neurodegenerative diseases including Alzheimer's disease (AD) Parkinson's disease, and Huntington's disease are marked by personality changes, memory loss (dementia), cognitive changes, blurred vision, insomnia, and loss of motor control. Despite substantial advances, these disorders are usually fatal or lead- to serious debilitation and dramatic worsening of the quality of life. As a result, there is a widely appreciated need to further elucidate the pathogenesis of these diseases and to develop effective therapies. Significant progress in elucidating molecular mechanisms that trigger the aggregation and the pathogenicity of proteins has enabled the design of novel and potentially powerful treatments. Nevertheless, little is known of the critical interactions in the complex in-vivo milieu which determines where and when protein deposition occurs in individual patients. Moreover, understanding of which molecular species are responsible for pathogenesis is far from complete.14-3-3 proteins are small, conserved scaffolding molecules that are expressed in all eukaryotes. They modulate the function of other proteins, primarily in a phosphorylation-dependent manner. They are abundantly expressed in the brain and are often thought to be involved in age-related neurodegenerative diseases. To date, several hundreds of 14-3-3 binding partners have been identified. This diverse group includes protein kinases, phosphatases, receptors, transcription factors, structural and cytoskeletal proteins, as well as small G-proteins and their regulators. Consequently, 14-3-3 proteins could be promising targets for therapeutic intervention. Previous studies on invertebrates have demonstrated the importance of these proteins for regulation of synaptic function, learning and memory. Nevertheless, the exact roles of 14-3-3 proteins in neurodegenerative diseases are still unclear. The present collection of articles brings together original research, reviews, and perspectives in the biology of 14-3-3 proteins and their possible relevance for therapy of neurodegenerative disease. An article by Obsilova and Obsil (2024) describes the molecular mechanisms through which 14-3-3 proteins regulate their binding partners. These mechanisms fall into three categories: 1) direct conformational modulation of the bound partner; 2) physical occlusion of sequence-specific or structural features on the surface of the target protein; and 3) scaffolding, which facilitates protein-protein interactions (Obsilova and Obsil, 2024).Although most binding partners of 14-3-3 proteins contain phosphorylated binding motifs, these proteins can also bind to non-phosphorylated motifs with high affinity. One example of phosphorylation-independent interaction is with exoenzyme S (ExoS), a bacterial ADP-ribosyltransferase toxin of Pseudomonas aeruginosa. This interaction is essential for toxin function. Structural studies on the complex between 14-3-3ζ and the ExoS peptide, identified as an amphipathic motif, revealed that the ExoS peptide binds to 14-3-3 mainly through hydrophobic contacts (Ottmann et al., 2007a). Another well-characterized peptide, the R18 peptide, derived from a phage display library, binds 14-3-3 proteins with high affinity through an amphipathic motif (Wang et al., 1999). 14-3-3 proteins modulate the activity of many enzymes including arylalkylamine N-acetyltransferase, tyrosine hydroxylase, tryptophan hydroxylase, yeast neutral trehalase, apoptosis signal-regulating kinases, protein kinases B-RAF and C-RAF, leucine-rich repeat protein kinase-2 (LRRK2), protein kinase C (PKC), calcium/calmodulin-dependent protein kinase kinases, death-associated protein kinase 2, phosphatidylinositol-4-kinase-III, protein phosphatase CDC25C, and E3 ligase neural precursor cell expressed developmentally down-regulated 4 ligase. Interestingly,14-3-3 protein binding motifs, are often located near a nuclear localization sequence (NLS) or nuclear export sequence (NES) and can thereby modulate the subcellular localization of its target (Muslin and Xing, 2000)). A well-known example is Forkhead box O transcription factors (FOXO), which are crucial for cell survival, DNA damage repair, and stress resistance (Gui and Burgering, 2021). Other examples are Class II histone deacetylases (HDAC4 and HDAC5), whose subcellular localization is controlled in a phosphorylation-dependent and 14-3-3 dependent manner through two 14-3-3 binding motifs: a NLS located between these two motifs, and a NES at the C-terminus, which is inactive in unphosphorylated HDACs. Obsilova and Obsil (2024) and o -Abstract Truncated-

14-3-3 Proteins Interact with Neurofilament Protein-L and Regulate Dynamic Assembly of Neurofilaments

Mutation Analysis of Neurofilament-Light Gene in Chinese Charcot-Marie-Tooth Disease

Study on Aggregate Formation Mechanism of HSPB8 Gene Mutation Resulting in CMT2L

Neurofilament dynamics and involvement in neurological disorders

Alternative stable conformation capable of protein misinteraction links tRNA synthetase to peripheral neuropathy.

Neurofilaments in health and disease

Interact with Neurofilament Protein-L ( NFL ) and Regulate Dynamic Assembly of Neurofilaments

Proteins in Aggregates Functionally Impact Multiple Neurodegenerative Disease Models by Forming Proteasome-Blocking Complexes

Neurofilament accumulations in amyotrophic lateral sclerosis patients' motor neurons impair axonal initial segment integrity

Cryptic amyloidogenic elements in mutant NEFH causing Charcot-Marie-Tooth 2 trigger aggresome formation and neuronal death

CMT2N-causing aminoacylation domain mutants enable Nrp1 interaction with AlaRS

Editorial: 14-3-3 proteins: possible importance in neurodegenerative diseases

Neurofilament light polypeptide gene N98S mutation in mice leads to neurofilament network abnormalities and a Charcot-Marie-Tooth Type 2E phenotype

Abstract 17551: Mapping the Interactome of FLNC in Restrictive Cardiomyopathy

Gain-of-Function Properties of a Dynamin 2 Mutant Implicated in Charcot-Marie-Tooth Disease

CK1δ/ε-mediated TDP-43 phosphorylation contributes to early motor neuron disease toxicity in amyotrophic lateral sclerosis

Restoring Mitofusin Balance Prevents Axonal Degeneration in a Charcot-Marie-Tooth Type 2A Model.

Axonal TDP-43 condensates drive neuromuscular junction disruption through inhibition of local synthesis of nuclear encoded mitochondrial proteins

The topology, structure and PE interaction of LITAF underpin a Charcot-Marie-Tooth disease type 1C

14-3-3 binding maintains the Parkinson's associated kinase LRRK2 in an inactive state